Robert Joseph Cobuzzi Jr. - Mar 18, 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (DFFN)

Role: President & CEO, Director
Signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person
Stock symbol: DFFN
Transactions as of: Mar 18, 2022
Transactions value $: $2,500
Form type: 4
Date filed: 3/22/2022, 07:30 AM
Previous filing: Feb 2, 2022
Next filing: Apr 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DFFN	Series C Convertible Preferred Stock	Purchase	$2.5K	+5K		$0.50	5K	Mar 18, 2022	Common Stock	5K	$0.50	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 18, 2022, the Reporting Person purchased 5,000 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Shares"), from the Issuer at a purchase price of $0.50 per Share in a private placement. The Shares have no voting rights, other than (i) each Share will be counted on an as converted basis, together with the Issuer's common stock as a single class, for purposes of determining the presence of a quorum at any meeting of the Issuer's stockholders at which a proposal related to a reverse stock split of the Issuer's common stock (a "Reverse Stock Split") will be voted upon, (ii) each Share is entitled to 80,000 votes on matters related to a Reverse Stock Split, provided that such votes must be cast For and Against each proposal on a "mirrored" basis proportional to the vote of the Issuer's common stockholders, and (iii) the right to vote as a class on certain specified matters directly related to the preferences, rights, and limitations of the Shares.

Content

On March 18, 2022, the Reporting Person purchased 5,000 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Shares"), from the Issuer at a purchase price of $0.50 per Share in a private placement. The Shares have no voting rights, other than (i) each Share will be counted on an as converted basis, together with the Issuer's common stock as a single class, for purposes of determining the presence of a quorum at any meeting of the Issuer's stockholders at which a proposal related to a reverse stock split of the Issuer's common stock (a "Reverse Stock Split") will be voted upon, (ii) each Share is entitled to 80,000 votes on matters related to a Reverse Stock Split, provided that such votes must be cast For and Against each proposal on a "mirrored" basis proportional to the vote of the Issuer's common stockholders, and (iii) the right to vote as a class on certain specified matters directly related to the preferences, rights, and limitations of the Shares.